---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-004423"
form_type: "8-K"
ticker: "APLS"
cik: "0001492422"
company_name: "Apellis Pharmaceuticals, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:44:02.854953+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Apellis reports preliminary 2022 EMPAVELI US net sales of ~$65M; NDA and MAA submitted

## Summary
- Preliminary unaudited 2022 US net product revenue for EMPAVELI ~$65 million.
- Submitted New Drug Application to US FDA and Marketing Authorization Application to EMA for pegcetacoplan.
- Appointed Dr. Caroline Baumal as Chief Medical Officer effective Q1 2023.
- Completed enrollment in Phase 2 ALS study; progressed late-stage pipeline with partner Sobi.
- Deployed ~100 field-based employees mid-2022 for US commercial launch.

## SEC filing metadata
- accession: 0001193125-23-004423
- form_type: 8-K
- ticker: APLS
- cik: 0001492422
- company_name: Apellis Pharmaceuticals, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492422/000119312523004423/0001193125-23-004423-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492422/000119312523004423/d436376d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-004423
- JSON: https://secwatch.observer/filing/0001193125-23-004423.json
- Plain text: https://secwatch.observer/filing/0001193125-23-004423.txt

## Key facts
- Earnings Releases
  Apellis Pharmaceuticals, Inc. reported FY 2022 results: revenue $65 million.
  - Period: FY 2022
  - Revenue: $65 million
  - Result: preliminary results
  source text: Caroline Baumal as Chief Medical Officer (effective Q1 2023) ~$65 million1 in U.S. net product sales Submitted sNDA for PRINCE & 48-week PEGASUS data Submitted sNDA for EMPAVELI injector Completed >800 patient years of systemic dosing2 Progressed late-stage clinical studies with partner Sobi Advanced early-stage
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492422/000119312523004423/0001193125-23-004423-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.